Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3390/microorganisms8070970

http://scihub22266oqcxt.onion/10.3390/microorganisms8070970
suck pdf from google scholar
32610445!7409236!32610445
unlimited free pdf from europmc32610445    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32610445 :   free

suck abstract from ncbi

pmid32610445
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)) #MMPMID32610445
  • Sayed AM; Alhadrami HA; El-Gendy AO; Shamikh YI; Belbahri L; Hassan HM; Abdelmohsen UR; Rateb ME
  • Microorganisms 2020[Jun]; 8 (7): ä PMID32610445show ga
  • The main protease (M(pro)) of the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was subjected to hyphenated pharmacophoric-based and structural-based virtual screenings using a library of microbial natural products (>24,000 compounds). Subsequent filtering of the resulted hits according to the Lipinski's rules was applied to select only the drug-like molecules. Top-scoring hits were further filtered out depending on their ability to show constant good binding affinities towards the molecular dynamic simulation (MDS)-derived enzyme's conformers. Final MDS experiments were performed on the ligand-protein complexes (compounds 1-12, Table S1) to verify their binding modes and calculate their binding free energy. Consequently, a final selection of six compounds (1-6) was proposed to possess high potential as anti-SARS-CoV-2 drug candidates. Our study provides insight into the role of the M(pro) structural flexibility during interactions with the possible inhibitors and sheds light on the structure-based design of anti-coronavirus disease 2019 (COVID-19) therapeutics targeting SARS-CoV-2.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    ä 7.8 2020